Lixte Biotechnology Announces Dosing Of First Patient In Phase 1b.2 Trial Assessing LIXTE's LB-100 And GSK's Immunotherapy Dostarlimab-gxly In Ovarian Clear Cell Carcinoma Trial
Lixte Biotechnology宣布在卵巢透明细胞癌试验中评估LIXTE的 LB-100 和葛兰素史克免疫疗法 dostarlimab-GXLY 的 1b.2 期试验中为首位患者服用剂量